Diagnosis and Management of Esophagogastric Varices.
Socrate PallioGiuseppinella MelitaEndrit ShahiniAlessandro VitelloEmanuele SinagraBarbara LattanziAntonio FacciorussoDaryl RamaiMarcello MaidaPublished in: Diagnostics (Basel, Switzerland) (2023)
Acute variceal bleeding (AVB) is a potentially fatal complication of clinically significant portal hypertension and is one of the most common causes of acute upper gastrointestinal bleeding. Thus, esophagogastric varices represent a major economic and population health issue. Patients with advanced chronic liver disease typically undergo an upper endoscopy to screen for esophagogastric varices. However, upper endoscopy is not recommended for patients with liver stiffness < 20 KPa and platelet count > 150 × 10 9 /L as there is a low probability of high-risk varices. Patients with high-risk varices should receive primary prophylaxis with either nonselective beta-blockers or endoscopic band ligation. In cases of AVB, patients should receive upper endoscopy within 12 h after resuscitation and hemodynamic stability, whereas endoscopy should be performed as soon as possible if patients are unstable. In cases of suspected variceal bleeding, starting vasoactive therapy as soon as possible in combination with endoscopic treatment is recommended. On the other hand, in cases of uncontrolled bleeding, balloon tamponade or self-expandable metal stents can be used as a bridge to more definitive therapy such as transjugular intrahepatic portosystemic shunt. This article aims to offer a comprehensive review of recommendations from international guidelines as well as recent updates on the management of esophagogastric varices.
Keyphrases
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- liver failure
- prognostic factors
- peritoneal dialysis
- atrial fibrillation
- squamous cell carcinoma
- respiratory failure
- ultrasound guided
- pulmonary embolism
- high throughput
- extracorporeal membrane oxygenation
- peripheral blood
- single cell
- bone marrow
- cell therapy
- pulmonary arterial hypertension